C-terminal maturation fragments of presenilin 1 and 2 control secretion of APP alpha and A beta by human cells and are degraded by proteasome

Mol Med. 1999 Mar;5(3):160-8.

Abstract

Background: Most early-onset forms of Alzheimer's disease are due to missense mutations located on two homologous proteins named presenilin 1 and 2 (PS1 and PS2). Several lines of evidence indicate that PS1 and PS2 undergo various post-transcriptional events including endoproteolytic cleavages, giving rise to 28-30 kD N-terminal (NTF) and 18-20 kD C-terminal (CTF) fragments that accumulate in vivo. Whether the biological activity of presenilins is borne by the processed fragments or their holoprotein precursor remains in question. We have examined the putative control of beta APP maturation by CTF-PS1/PS2 and the catabolic process of the latter proteins by the multicatalytic complex, proteasome.

Materials and methods: We transiently and stably transfected HEK293 cells with CTF-PS1 or CTF-PS2 cDNA. We examined these transfectants for their production of A beta 40, A beta 42, and APP alpha by immunoprecipitation using specific polyclonals. The effect of a series of proteases inhibitors on the immunoreactivity of CTF-PS1/PS2 was examined by Western blot. Finally, the influence of proteasome inhibitors on the generation of beta APP fragments by CTF-expressing cells was assessed by combined immunoprecipitation and densitometric analyses.

Results: We showed that transient and stable transfection of CTF-PS1 and CTF-PS2 cDNAs in human cells leads to increased secretion of APP alpha and A beta, the maturation products of beta APP. Furthermore, we demonstrated that two proteasome inhibitors, lactacystin and Z-IE(Ot-Bu)A-Leucinal, prevent the degradation of both CTFs. Accordingly, we established that proteasome inhibitors drastically potentiate the phenotypic increased production of APP alpha and A beta elicited by CTF-PS1/PS2.

Conclusion: Our data establish that the C-terminal products of PS1 and PS2 maturation exhibit biological activity and in particular control beta APP maturation upstream to alpha-and beta/gamma-secretase cleavages. This function is directly controlled by the proteasome that modulates the intracellular concentration of CTFs.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetylcysteine / analogs & derivatives
  • Acetylcysteine / pharmacology
  • Amyloid beta-Peptides / metabolism*
  • Amyloid beta-Protein Precursor / metabolism*
  • Cysteine Endopeptidases / drug effects
  • Cysteine Endopeptidases / metabolism*
  • Cysteine Proteinase Inhibitors / pharmacology
  • Enzyme Inhibitors / pharmacology
  • Glycopeptides / pharmacology
  • Humans
  • Leucine / analogs & derivatives
  • Leucine / pharmacology
  • Leupeptins / pharmacology
  • Membrane Proteins / drug effects
  • Membrane Proteins / genetics
  • Membrane Proteins / metabolism*
  • Multienzyme Complexes / drug effects
  • Multienzyme Complexes / metabolism*
  • Oligopeptides / pharmacology
  • Pepstatins / pharmacology
  • Presenilin-1
  • Presenilin-2
  • Proteasome Endopeptidase Complex
  • Recombinant Proteins / genetics
  • Recombinant Proteins / metabolism
  • Sulfones / pharmacology
  • Transfection

Substances

  • Amyloid beta-Peptides
  • Amyloid beta-Protein Precursor
  • Cysteine Proteinase Inhibitors
  • Enzyme Inhibitors
  • Glycopeptides
  • Leupeptins
  • Membrane Proteins
  • Multienzyme Complexes
  • Oligopeptides
  • PSEN1 protein, human
  • PSEN2 protein, human
  • Pepstatins
  • Presenilin-1
  • Presenilin-2
  • Recombinant Proteins
  • Sulfones
  • benzyloxycarbonyl-isoleucyl-glutamyl(O-tert-butyl)-alanyl-leucinal
  • Streptomyces pepsin inhibitor
  • lactacystin
  • 4-(2-aminoethyl)benzenesulfonylfluoride
  • Cysteine Endopeptidases
  • Proteasome Endopeptidase Complex
  • Leucine
  • E 64
  • benzyloxycarbonylleucyl-leucyl-leucine aldehyde
  • phosphoramidon
  • pepstatin
  • Acetylcysteine